Small ubiquitin-like modifier (SUMO) modification of the androgen receptor attenuates polyglutamine-mediated aggregation - Wikidata - wikimedia - TriplyDB

Small ubiquitin-like modifier (SUMO) modification of the androgen receptor attenuates polyglutamine-mediated aggregation

Small ubiquitin-like modifier (SUMO) modification of the androgen receptor attenuates polyglutamine-mediated aggregation

http://www.wikidata.org/entity/Q30377831

about

SUMOylation of the mitochondrial fission protein Drp1 occurs at multiple nonconsensus sites within the B domain and is linked to its activity cycle Sumoylation of critical proteins in amyotrophic lateral sclerosis: emerging pathways of pathogenesis Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy Dynamic Sumoylation of a Conserved Transcription Corepressor Prevents Persistent Inclusion Formation during Hyperosmotic Stress Disrupting SUMOylation enhances transcriptional function and ameliorates polyglutamine androgen receptor-mediated disease.Sumoylation of the astroglial glutamate transporter EAAT2 governs its intracellular compartmentalization Differential effects of sumoylation on transcription and alternative splicing by transcription elongation regulator 1 (TCERG1).Ubiquitin/proteasome pathway impairment in neurodegeneration: therapeutic implications SUMOylation of GPS2 protein regulates its transcription-suppressing function.Neuronal SUMOylation: mechanisms, physiology, and roles in neuronal dysfunction.Keratin hypersumoylation alters filament dynamics and is a marker for human liver disease and keratin mutation.Integration of Orthogonal Signaling by the Notch and Dpp Pathways in Drosophila.SUMO-1 modification on K166 of polyQ-expanded ataxin-3 strengthens its stability and increases its cytotoxicity.Cardiac function and disease: emerging role of small ubiquitin-related modifier.Sumoylation inhibits alpha-synuclein aggregation and toxicity.SUMOylation regulates ciliary localization of olfactory signaling proteins.Post-translational modifications of nuclear receptors and human disease IκB kinases modulate the activity of the androgen receptor in prostate carcinoma cell lines.The in vivo role of androgen receptor SUMOylation as revealed by androgen insensitivity syndrome and prostate cancer mutations targeting the proline/glycine residues of synergy control motifs.Mechanisms mediating spinal and bulbar muscular atrophy: investigations into polyglutamine-expanded androgen receptor function and dysfunction.Trinucleotide repeats and protein folding and disease: the perspective from studies with the androgen receptor.Targets and consequences of protein SUMOylation in neurons.Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease.Sumoylation in neurodegenerative diseases.SUMO rules: regulatory concepts and their implication in neurologic functions.Ubiquitin and ubiquitin-like proteins in cardiac disease and protection.SUMO-1 Gene Silencing Inhibits Proliferation and Promotes Apoptosis of Human Gastric Cancer SGC-7901 Cells.Polyglutamine androgen receptor-mediated neuromuscular disease.Ubiquitin-dependent and independent roles of SUMO in proteostasis.Proteins Containing Expanded Polyglutamine Tracts and Neurodegenerative Disease.Post-translational Modifications and Protein Quality Control in Motor Neuron and Polyglutamine Diseases.Dynamic SUMOylation is linked to the activity cycles of androgen receptor in the cell nucleus.SUMOylation of AhR modulates its activity and stability through inhibiting its ubiquitination.SUMOylation regulates the intracellular fate of ZO-2.Sumo E2 enzyme UBC9 is required for efficient protein quality control in cardiomyocytes.Undoing SUMO aids polyQ AR.Interplay between sumoylation and phosphorylation for protection against α-synuclein inclusions.Fighting polyglutamine disease by wrestling with SUMO.SUMOylation attenuates the aggregation propensity and cellular toxicity of the polyglutamine expanded ataxin-7.Failed mitochondrial import and impaired proteostasis trigger SUMOylation of mitochondrial proteins.

P2860

Q24318317-A6BB9FC1-F701-452C-B6F6-A02C296C7DC7 Q26866679-29B813B2-A7FC-4FA3-B2F5-D421CEA23AA2 Q27007098-9B2553E3-E27C-4938-8426-7899C924D1E3 Q28552752-43F9B14F-18D2-424A-BA0B-0FF63D25F245 Q30405382-7E108564-AA9B-4914-BCC7-E02FC44911CE Q33769417-9922B31A-491A-4883-9D4C-CCBB18734731 Q33832763-E35DBF55-C145-4F54-9F0E-CCA90D38012C Q34012297-1814B717-5B48-4543-8297-CC48D83643AE Q34081460-8543FD18-3DCC-4D37-80C2-C06C60617D48 Q34295237-4156D294-9CCE-437A-9F7C-FDF15A4AAC6C Q34503272-03E86965-8BFB-46C4-8337-DD59209F71E5 Q34518118-A0800343-9D47-42A4-8B2A-C8030782E971 Q34575362-5BD668C1-2C44-4D39-9CF5-DE0E34D0666F Q35032636-D2352561-74D2-4B09-9F60-877126125409 Q35102441-62E6AA29-716A-461B-80B3-8896DCB7D441 Q35687500-B5AF4456-2FC6-40D4-B4D7-2B06F03035F9 Q35842790-928BBD7A-145B-413A-9B44-AB4716124269 Q35882191-B5067D66-7608-4F6E-9AE2-8368D79F1317 Q36225738-4108DAAF-4F71-4FED-82C0-4DDAA561F79E Q36844932-B941DA74-D407-49B3-A1AD-B001D7814351 Q37474263-4836D5E7-9999-45A4-9963-C0DAFC56C1E8 Q37728628-55DAC1BD-BD6B-4677-B6D1-1FFD6D6D4478 Q37839534-EEF63D6C-3697-4DFD-9CE0-880CE40B105D Q38046126-4FA19858-93AE-4419-B717-B0244249FD27 Q38132691-7DE7B257-C426-4882-BA42-1D9D60ABDF58 Q38663141-79241D13-9B3F-488B-9726-3D75BACC3721 Q38715505-916A86BF-E435-4418-8B01-5C4451A8731A Q38836469-C011401B-8720-40EB-930A-52BDA8EB4B10 Q38874015-FBDE72AA-C8EF-4406-A4AF-6EFCD3E5CCCA Q39124557-EA094AC0-8F32-4573-864A-50FC5319E923 Q39241744-436351D3-D5AA-465C-BFF7-A961039281C3 Q39297900-CD0D01F6-F7B0-446E-B10B-520A77939DCD Q39365756-B926DF90-3F01-42E6-AD61-B27F33575C82 Q39412884-83A19E42-8137-47F5-8098-1DCB64D017A1 Q42066873-B4F13F1F-5E69-46C4-8929-95A86CEC4AD4 Q42551916-61F36DDE-7AA7-4E34-8D90-35FBEB693360 Q42983118-EB373EA8-0561-4B54-85BE-DC5C90856891 Q43135526-E9517FC4-E20C-4F97-8CC6-CF54ECD05ABF Q43258139-8D8A4D5B-DD8D-4957-AAEF-E22FAE8897A3 Q47354909-12F71E33-59AF-464A-8709-12A3FFDD340B

P2860

Small ubiquitin-like modifier (SUMO) modification of the androgen receptor attenuates polyglutamine-mediated aggregation

http://www.wikidata.org/entity/Q30377831

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Small ubiquitin-like modifier ...... glutamine-mediated aggregation

@ast

Small ubiquitin-like modifier ...... glutamine-mediated aggregation

@en

type

label

Small ubiquitin-like modifier ...... glutamine-mediated aggregation

@ast

Small ubiquitin-like modifier ...... glutamine-mediated aggregation

@en

prefLabel

Small ubiquitin-like modifier ...... glutamine-mediated aggregation

@ast

Small ubiquitin-like modifier ...... glutamine-mediated aggregation

@en

P1433

Q30377831-CE2CAE23-2197-48A5-AE6C-2394DBD299A9

P1476

Q30377831-501EBC40-0E41-4977-94B0-283B43F9B533

P2093

Q30377831-569EA142-BB4A-4E81-87CF-8079C48B3183

Q30377831-8790BA9E-E50F-470F-AF76-679919033D41

Q30377831-8837FE9F-4A93-4F69-8AC4-6E50184BD1CF

Q30377831-E403F3A2-14FF-4917-ADE0-3EFAF3C156D0

P2860

Q30377831-0F6F6103-B8D6-4A02-911E-7E403E16C09F

Q30377831-10475C15-F3AA-471D-825F-4139FC1D6979

Q30377831-15143EFF-D8CA-4544-822F-4BDFAA45F967

Q30377831-15AE7D4E-BDDD-4C13-8A88-53D2591272C1

Q30377831-17189369-698F-4CAE-9917-B54EAC955213

Q30377831-193F2164-E959-438F-83AD-A86AE6D391B2

Q30377831-1A7457DE-FD06-41A4-8C00-384BBA55A0E1

Q30377831-1B7F96EF-4461-4F72-A89F-70A78521DF1C

Q30377831-1CFB1A8C-2635-4EE4-A8EA-7BF80AD3C735

Q30377831-203B837B-31EE-4052-95B8-5A60D15A2F54

P304

Q30377831-D2E81421-6CF8-43CC-9537-DCA70D00E21A

P31

Q30377831-0902EE67-173C-433E-89A1-DF341B402358

P356

Q30377831-DCF0BF9D-9D4F-49C9-9685-F1C7E9AA23A3

P407

Q30377831-7DE4B26C-842B-4F41-82CD-ECA783B18E0E

P433

Q30377831-2A27DD78-60F5-46D3-BB7D-8E55F3586801

P478

Q30377831-760D86C9-7BC3-41E1-99B7-5E691E6BF3A7

P50

Q30377831-D44CFD8D-84D8-4E89-8C93-F5ACBF8E6959

P577

Q30377831-5207219A-25AA-4D1C-8CD0-4154C76A31A8

P698

Q30377831-3777D19E-8AB9-4644-8C1B-A05D3C10DD10

P932

Q30377831-99ABBDD3-D03D-4000-A571-1B5B04B24DAB

P356

JBC.M109.011494

P1433

Journal of Biological Chemistry

P1476

Small ubiquitin-like modifier ...... glutamine-mediated aggregation

@en

P2093

Andrew P Lieberman

http://www.w3.org/2001/XMLSchema#string

Monzy Thomas

http://www.w3.org/2001/XMLSchema#string

Nahid Dadgar

http://www.w3.org/2001/XMLSchema#string

Sarmistha Mukherjee

http://www.w3.org/2001/XMLSchema#string

P2860

RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation

SUMO modification of Huntingtin and Huntington's disease pathology

Transcription factor Sp3 is silenced through SUMO modification by PIAS1

NXP-2 association with SUMO-2 depends on lysines required for transcriptional repression

PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies

The nucleoporin RanBP2 has SUMO1 E3 ligase activity

Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3

A synergy control motif within the attenuator domain of CCAAT/enhancer-binding protein alpha inhibits transcriptional synergy through its PIASy-enhanced modification by SUMO-1 or SUMO-3

Protein inhibitor of activated signal transducer and activator of transcription 1 interacts with the N-terminal domain of mineralocorticoid receptor and represses its transcriptional activity: implication of small ubiquitin-related modifier 1 modifi

Molecular features of human ubiquitin-like SUMO genes and their encoded proteins

P304

21296-21306

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M109.011494

http://www.w3.org/2001/XMLSchema#string

P407

P433

32

http://www.w3.org/2001/XMLSchema#string

P478

284

http://www.w3.org/2001/XMLSchema#string

P50

Jorge Iñiguez-lluhí

P577

2009-06-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19497852

http://www.w3.org/2001/XMLSchema#string

P932

2755854

http://www.w3.org/2001/XMLSchema#string